Selected Start-Ups (06/00)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: BioProtocol Inc.'s web site, Bioprotocol.com, will offer life scientists free access to high quality protocols to guide their research. Locus Discovery Inc. has a computational approach for designing small molecule therapeutics that can act as inhibitors or activators of protein activity. Morphotek Inc. is developing an in vivo technology that can alter the genome of microbe, plant, and mammal host cells to produce organisms with commercially viable output traits. NitroOSystems Inc. hopes that its tolerance-free nitrate therapy will become the standard of care for the treatment of angina, congestive heart failure, hypertension, and other cardiovascular disorders. Repair Inc. is developing therapeutics for cardiovascular disease based on its proprietary drug delivery and angiogenesis technologies. Unipharm Technologies Limited claims that its approach to drug delivery will render existing quick dissolve oral dosage forms unnecessary and aid drugs that have negative esophgeal or gastric mucosal effects.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.